TLX
Telix Pharmaceuticals Limited
There isn't enough reported data to score TLX yet.
TLX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Weak |
TLX's profitability and balance sheet are currently weak. There isn't enough data to rate its revenue and cash flow.
TLX PE Valuation
TLX has no meaningful PE right now: it lost money over the past year.
TLX Forward outlook
There aren't enough analyst estimates for TLX to show an outlook.
TLX Earnings Per Share
TLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $803.8M | +50% |
| Q4 2024 | $536.1M | +178% |
| Q4 2023 | $192.8M | +107% |
| Q2 2023 | $151.2M | +818% |
| Q4 2022 | $93.1M | +2803% |
| Q2 2022 | $16.5M | +726% |
| Q4 2021 | $3.2M | +30% |
| Q2 2021 | $2M | +81% |
TLX's revenue has grown year over year for 13 quarters in a row: $804M last quarter, up 763% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 3.7% | +11 points |
| Q4 2024 | 10% | +275 points |
| Q4 2023 | -5.5% | +1060 points |
| Q2 2023 | 14% | +1100 points |
| Q4 2022 | -7.1% | +801 points |
| Q2 2022 | -264% | +987 points |
| Q4 2021 | -1065% | +378 points |
| Q2 2021 | -1086% | -195 points |
TLX's operating margin was 3.7% last quarter, up 11 points from the same quarter a year ago.
TLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$43M | -319% |
| Q4 2024 | $19.7M | +626% |
| Q4 2023 | $2.7M | +$8.5M |
| Q2 2023 | $7M | +$49.9M |
| Q4 2022 | -$5.8M | +$15.9M |
| Q2 2022 | -$42.8M | -$23M |
| Q4 2021 | -$21.7M | -255% |
| Q2 2021 | -$19.8M | -$7.1M |
TLX has burned cash in most quarters: −$14M over the past year, against −$90M the year before.
TLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -7.3M shares |
| 1 year | +6.8% | +21.5M shares |
| 3 years | +63% | +131M shares |
| 5 years | +774% | +299M shares |
| Available history | +774% | +299M shares |
TLX has 338M diluted shares, up 6.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q2 2023 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
| Q4 2020 | — |
| Q2 2020 | — |
TLX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 5.1x | High |
| Q4 2024 | -1.6x | Net Cash |
TLX's net debt is about 5.1 years of its operating earnings (EBITDA).
TLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 10.8 | Oversold |
TLX's weekly RSI is 44 (neutral) and its Stochastic is 11 (oversold).
TLX PE vs Healthcare Sector
| Metric | TLX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TLX has no meaningful PE right now: it lost money over the past year.
TLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 7.7% below |
| 20 week MA | $10.8 | 13% below |
| 50 week MA | $9.66 | 3.1% below |
| 100 week MA | $12.1 | 23% below |
TLX is in a downtrend: it's below all four of its weekly moving averages, and 23% below its 100-week average.
TLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $14.9 | $15.6 | +5.1% |
| 2025 | $15.6 | $8.03 | -49% |
| 2026 YTD | $8.03 | $9.36 | +17% |
TLX has finished lower in one of the last two years. It's up 17% so far in 2026.